Figure 1. Competition From Skinny-Label and Full-Label Biosimilars for Biologics Approved by the US Food and Drug Administration (FDA) Through 2021.

^aThis projected period of competition was based on the latest expiration date among patents and regulatory exclusivities protecting the indication(s) carved out of the biologic’s label.

^bThis projected period of competition was based on the latest expiration date among regulatory exclusivities protecting the indication(s) carved-out of the biologic’s label.

^cThis period of competition represents when only skinny-label biosimilars were commercially available but a full-label biosimilar could have been marketed based on the expiration dates of the identified patents and regulatory exclusivities protecting the carved-out indication(s).

^dTwo full-label etanercept biosimilars were approved by the FDA but are not expected to be marketed until 2029.

^eThis bar is shaded white.